Etoposide (topoisomerase II inhibitor), camptothecin (topoisomerase I inhibitor), and carboplatin were used for dose–response and time-course studies on control and UHRF1-knockdown Y79 retinoblastoma cells (Fig. 1). This evidence concerns the gene UHRF1 and retinoblastoma.